A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model
Microbiome Research Reports · 09.02.2026 · 6 (1)
DOI: 10.20517/mrr.2025.117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiome Research Reports, online erschienen am 09.02.2026. Verfasst von Uk Jin Jeong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (PD-1) therapy, have improved cancer treatment outcomes, yet durable benefit is achieved in only a subset of patients. Growing evidence implicates the gut microbiome as a modulator of ICI responsiveness, but defined and experimentally validated microbial strategies remain limited. This study aimed to identify responder-associated gut microbes and to evaluate a defined bacterial consortium for enhancing PD-1 blockade efficacy.
Methods
Publicly available shotgun metagenomic datasets from anti-PD-1-treated cancer patients were re-analyzed to compare gut microbiome profiles between responders and non-responders. Bacterial taxa reproducibly enriched in responders were selected based on consistency across analytical criteria and cultivability and assembled into a four-strain consortium (UJ-04). The immune-adjuvant potential of UJ-04, alone or combined with anti-PD-1 therapy, was evaluated in a B16-F10 melanoma mouse model, with tumor growth and immune responses assessed by flow cytometry.
Results
Metagenomic re-analysis identified four commensal bacterial taxa consistently enriched in responder patients, forming the defined UJ-04 consortium. While UJ-04 alone showed minimal antitumor activity, combination treatment with anti-PD-1 significantly enhanced tumor growth inhibition compared with anti-PD-1 monotherapy. This effect was accompanied by increased intratumoral CD8+ T cells and natural killer cells, with concordant immune trends in peripheral compartments.
Conclusion
A responder-informed, defined microbial consortium functionally translates clinical microbiome associations into in vivo validation and enhances PD-1 blockade efficacy by modulating host antitumor immunity. These findings support defined bacterial consortia as microbiome-based immunomodulatory adjuncts for immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Section of Hematology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06511, USA.
- Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- BioMe Inc., Seoul 02455, Republic of Korea.
Zitieren
APA
Jeong, U. J., Ali, M., Park, Y. J., You, J. S., & Yoon, S. S. (2026). A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model. Microbiome Research Reports, 6(1). https://doi.org/10.20517/mrr.2025.117
Vancouver
Jeong UJ, Ali M, Park YJ, You JS, Yoon SS. A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model. Microbiome Research Reports. 2026;6(1). doi:10.20517/mrr.2025.117
BibTeX
@article{Jeong2026,
author = {Jeong, Uk Jin and Ali, Mohammed and Park, Yun Jee and You, Jin Sun and Yoon, Sang Sun},
title = {A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model},
journal = {Microbiome Research Reports},
year = {2026},
volume = {6},
number = {1},
doi = {10.20517/mrr.2025.117}
}
EUVIMED